<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Roussou, M.</style></author><author><style face="normal" font="default" size="100%">Kastritis, E.</style></author><author><style face="normal" font="default" size="100%">Christoulas, D.</style></author><author><style face="normal" font="default" size="100%">Migkou, M.</style></author><author><style face="normal" font="default" size="100%">Gavriatopoulou, M.</style></author><author><style face="normal" font="default" size="100%">Grapsa, I.</style></author><author><style face="normal" font="default" size="100%">Psimenou, E.</style></author><author><style face="normal" font="default" size="100%">Gika, D.</style></author><author><style face="normal" font="default" size="100%">Terpos, E.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents</style></title><secondary-title><style face="normal" font="default" size="100%">Leukemia Research</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">bortezomib</style></keyword><keyword><style  face="normal" font="default" size="100%">Conventional chemotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Lenalidomide</style></keyword><keyword><style  face="normal" font="default" size="100%">multiple myeloma</style></keyword><keyword><style  face="normal" font="default" size="100%">renal impairment</style></keyword><keyword><style  face="normal" font="default" size="100%">Thalidomide</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955985354&amp;doi=10.1016%2fj.leukres.2010.04.024&amp;partnerID=40&amp;md5=4a9ac4cb8e98221b9efa08637738a58a</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">34</style></volume><pages><style face="normal" font="default" size="100%">1395 - 1397</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The purpose of this analysis was to assess the effect of novel agent-based regimens on the improvement of renal impairment (RI) in newly diagnosed patients with multiple myeloma. Ninety-six consecutive patients with RI received conventional chemotherapy (CC)-based regimens (n= 32), IMiDs-based regimens (n= 47) or bortezomib-based regimens (n= 17) as frontline therapy. Improvement of RI was more frequent in patients treated with novel agents (79% in IMiD- and 94% in bortezomib-treated groups versus 59% in CC-treated group; p= 0.02). Bortezomib-based regimens and CrCl &gt; 30 ml/min at baseline independently correlated with a higher probability of at least renal partial response (PRrenal) and with a shorter time to PRrenal or better. Thus bortezomib-based regimens may be the preferred treatment for newly diagnosed myeloma patients with RI. © 2010 Elsevier Ltd.</style></abstract><issue><style face="normal" font="default" size="100%">10</style></issue><notes><style face="normal" font="default" size="100%">Cited By :52Export Date: 21 February 2017</style></notes></record></records></xml>